Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Quizartinib in MDS and MDS/MPN with FLT3 or CBL Mutations
NCT04493138Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quizartinib in myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2020; status: active, not recruiting.
02
Drugs
quizartinib
03
Conditions
myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04493138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493138.